人工智能增强的超快速PSMA-PET在前列腺癌分期中的应用
本研究纳入357例前列腺癌患者的全身[68Ga]Ga-PSMA-11 PET数据集,比较超快速PSMA-PET与人工智能增强后的超快速PET在miTNM各区域的分期准确性。AI增强显著提高了多数miTNM区域的图像质量和检出率,但对M1c类别改善不显著,对体积小、摄取低的病灶敏感性有限。
要点
- AI增强使超快速PSMA-PET各miTNM区域检出率平均提高17.9%。
- T、N、M1a、M1b区域检出率显著改善,M1c区域改善不显著。
- 漏诊病灶的SUVmax和病灶尺寸小于检出病灶(如N区:SUVmax 9.5 vs 26.5;4 vs 10 mm)。
核心结论
- 基于AI的图像增强使图像质量和区域检出率平均提高17.9%。
- 由于合成PET对小病灶和低摄取病灶的敏感性有限,潜在临床用途可能是对高肿瘤负荷和高PSMA摄取接受PSMA放射性配体治疗的患者进行疾病监测。
- 远处转移检出率的改善不显著,提示需要更多训练数据以确保对出现频率较低病灶的稳健结果。
- 未来关于加速PSMA-PET的研究似乎是必要的。
研究设计与样本
- 共纳入357例全身[68Ga]Ga-PSMA-11 PET数据集,患者接受标准速度和超快速两次数字PET扫描(床速:0.6-1.2 mm/s vs 50 mm/s)。
- 采用改进的pix2pixHD生成对抗网络增强超快速图像,以286个数据集训练,其余71个数据集评估。
- 按PROMISE V2.0提出的miTNM区域,分别比较超快速PSMA-PET和AI增强超快速PET与参考标准PET的分期准确性。
主要发现
- AI网络较未增强图像数据显著改善多数miTNM区域的视觉图像质量和检出率:T区69.6% vs 43.5%(p<0.05);N区46.3% vs 27.8%(p<0.01);M1a区64.4% vs 47.5%(p<0.01);M1b区85.7% vs 72.1%(p<0.01)。
- M1c类别改善不显著(42.9% vs 28.6%,p>0.05)。
- 漏诊病灶较检出病灶SUVmax更小、病灶尺寸更小(以N区为例:SUVmax 9.5 vs 26.5;4 vs 10 mm)。
- 所有miTNM区域的病灶SUVmax在超快速与参考标准PET之间均有显著差异,而AI增强与参考标准PET之间仅在T区有显著差异。
临床怎么用
- 由于合成PET对小病灶和低摄取病灶的敏感性有限,作者认为潜在临床用途可能是对高肿瘤负荷和高PSMA摄取接受PSMA放射性配体治疗的患者进行疾病监测。
- 作者指出远处转移检出率的改善不显著,提示需要更多训练数据以确保对出现频率较低病灶的稳健结果。
- 作者认为未来关于加速PSMA-PET的研究似乎是必要的。
局限性
- 合成PET对小病灶和低摄取病灶的敏感性有限。
- 远处转移检出率的改善不显著。
- 需要更多训练数据以确保对出现频率较低病灶的稳健结果。
- 未来关于加速PSMA-PET的研究似乎是必要的。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PSMA-PET is a reference standard examination for patients with prostate cancer, but even using recently introduced digital PET detectors image acquisition with standard field-of-view scanners is still in the range of 20 min. This may cause limited access to examination slots because of the growing demand for PSMA-PET. Ultra-fast PSMA-PET may enhance throughput but comes at the cost of poor image quality. The aim of this manuscript is to evaluate the accuracy of AI-enhanced ultra-fast PSMA-PET for staging of patients with prostate cancer. METHODS: A total number of 357 whole-body [68Ga]Ga-PSMA-11 PET datasets were included. Patients underwent two digital PET scans, one at standard and one at ultra-fast speed (table speed: 0.6-1.2 mm/s vs. 50 mm/s). A modified pix2pixHD generative adversarial network to enhance the ultra-fast images was trained with 286 datasets and evaluated with the remaining 71 datasets. The staging accuracy of ultra-fast PSMA-PET and AI-enhanced ultra-fast PET was compared with the reference standard PET separately for miTNM regions proposed by PROMISE V2.0. RESULTS: The AI-network significantly improved the visual image quality and detection rate in most miTNM regions compared with the non-enhanced image data (T: 69.6% vs. 43.5%, p < 0.05; N: 46.3% vs. 27.8%, p < 0.01; M1a 64.4% vs. 47.5%, p < 0.01; M1b: 85.7% vs. 72.1%, p < 0.01). However, improvement was not significant for the M1c category (42.9 vs. 28.6%, p > 0.05). Missed lesions had a smaller SUVmax and lesion size compared with detected lesions (exemplary for N: 9.5 vs. 26.5 SUVmax; 4 vs. 10 mm). SUVmax values of lesions were significantly different in all miTNM regions between the ultra-fast and reference standard PET, but only in the T-region between the AI-enhanced and reference standard PET. CONCLUSION: The AI-based image enhancement improved image quality and region detection rates by a mean of 17.9%. As the sensitivity of synthetic PET for small and low-uptake lesions was limited, a potential clinical use case could be disease monitoring in patients with high tumor volume and PSMA uptake undergoing PSMA radioligand therapy. The improvement in detection rate of distant metastases was not significant. This indicates that more training data is needed to ensure robust results also for lesions that have lower appearance frequency. Future studies on accelerated PSMA-PET seem warranted.
引用
- Kersting D, Borys K, Küper A, et al. Staging of prostate Cancer with ultra-fast PSMA-PET scans enhanced by AI. Eur J Nucl Med Mol Imaging. 2025. PMID: 39794510. doi:10.1007/s00259-024-07060-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。